Clinical practice guidelines for sustained neuromuscular blockade in the adult critically iii patient

American Journal of Health-System Pharmacy

Volumn 59, Issue 2, 2002, Pages 179-195

  Dasta, Joe ^a   Fish, Doug ^a   Hassan, Erkan ^a   Horst, H Mathilda ^a   Jackson, Carlayne E ^a   Kaiser, Karen ^a   Kelly, Kathleen M ^a   Schoenberger, Carl ^a   Schoonover, Lori ^a   Takaniski, Gayle ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Critical illness; Dosage schedules; Guidelines; Hospitals; Skeletal muscle relaxants

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ATRACURIUM; ATRACURIUM BESILATE; BENZYLISOQUINOLINE DERIVATIVE; CARBAMAZEPINE; CISATRACURIUM; CORTICOSTEROID; CURARE; DOXACURIUM; LAUDANOSINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; OPIATE; PANCURONIUM; PANCURONIUM BROMIDE; PHENYTOIN; PIPECURONIUM; PIPECURONIUM BROMIDE; RAPACURONIUM BROMIDE; ROCURONIUM; SEDATIVE AGENT; STEROID; THEOPHYLLINE; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VECURONIUM;

ADULT; ARTIFICIAL VENTILATION; BRONCHOSPASM; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG ANTAGONISM; DRUG CHOICE; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; MAINTENANCE THERAPY; MEDICAL SOCIETY; MUSCLE SPASM; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; OSSIFYING MYOSITIS; OXYGEN CONSUMPTION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUADRIPLEGIA; REVIEW; SEIZURE;

EID: 0037081979     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.2.179     Document Type: Review

References (78)

1. Sedation, analgesia, and neuromuscular blockade of the critically ill adult: Revised clinical practice guidelines for 2002
2. Patterns of neurophysiological abnormality in prolonged critical illness
3. Applied pharmacology of common neuromuscular blocking agents in critical care
4. Paralysis in the critically ill: Intermittent bolus pancuronium compared with continuous infusion
5. Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit
6. Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients?
7. Postal survey on the long-term use of neuromuscular block in the intensive care unit
8. Rocuronium bromide in the ICU: Dose finding and pharmacokinetics
9. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients
10. Residual neuromuscular blockade after cardiac surgery: Pancuronium vs rocuronium
11. Selective rocuronium pharmacodynamics and kinetics during ICU infusion
12. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents
13. Long-term administration of pancuronium and pipecuronium in the intensive care unit
14. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients
15. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients
16. Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants
17. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation
18. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients
19. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cisatracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit
20. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients
21. The cerebral and cardiovascular effects ofcisatracurium and atracurium in neurosurgical patients
22. Effects of cisatracurium on cerebral and cardiovascular hemodynamics in patients with severe brain injury
23. Laudanosine and atracurium concentrations in a patient receiving long-term atracurium infusion
24. Prolonged weakness after cisatracurium infusion: A case report
25. Nondepolarizing neuromuscular blocking drugs in the intensive care unit: A clinical review
26. Use of neuromuscular blocking drugs in intensive care unit patients
27. Cisatracurium in intensive care
28. Benzylisochinoline muscle relaxants in clinical practice
29. The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients
30. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients
31. Doxacurium infusion in critically ill patients with atracurium tachyphylaxis
32. Atracurium and status epilepticus
33. Cross-resistance to both atracurium- and vecuronium-induced neuromuscular blockade in a critically ill patient
34. Prolonged weakness after infusion of atracurium in two intensive care unit patients
35. Prolonged weakness after the withdrawal of atracurium
36. Prolonged paralysis with atracurium infusion: A case report
37. Persistent paralysis after prolonged use of atracurium in the absence of corticosterolds
38. Prolonged neuromuscular blockade in two critically ill patients treated with atracurium
39. Comparison of neuromuscular recovery after paralysis with atracurium versus vecuronium in an ICU patient with renal insufficiency
40. Continuous midazolam/atracurium infusions for the management of increased intracranial pressure
41. Tetanus and rocuronium in the intensive care unit
42. Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis
43. Comparison of train-of-four and best clinical assessment during continuous paralysis
44. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit
45. Neuromuscular blocking agents in the intensive care unit: A two-edged sword
46. Monitoring neuromuscular blockade in the adult ICU
47. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU
48. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents
49. Peripheral nerve stimulation and clinical assessment for dosing of neuromuscular blocking agents in critically ill patients
50. Monitoring neuromuscular blockade in the critically ill
51. Technical and interpretative problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit
52. Inconsistency with train-of-four monitoring in a critically ill paralyzed patient
53. Train-of-four: To use or not to use
54. Neuromuscular monitoring: Does it make a difference?
55. Sedation and chemical relaxation in critical pulmonary illness: Suggestions for patient assessment and drug monitoring
56. Therapeutic paralysis of critically ill trauma patients: Perceptions of patients and their family members
57. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature
58. Acute weakness syndromes in critically ill patients - A reappraisal
59. Reversible paralysis with status asthmaticus, steroids, and pancuronium: Clinical electrophysiological correlates
60. Acute myopathy of intensive care: Clinical, electromyographic, and pathological aspects
61. The use of neuromuscular blocking drugs in intensive care practice
62. Muscle weakness in mechanically ventilated patients with severe asthma
63. EMG findings in acute myopathy with status asthmaticus, steroids and paralytics: Clinical and electrophysiologic correlation
64. Critical care myopathy: An electrophysiological and histological study
65. Critical illness myopathy and neuropathy
66. Muscle weakness and difficulty in weaning from the ventilator in the critical care unit
67. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids
68. Acute necrotizing myopathy of intensive care: Electrophysiologic studies
69. Doxacurium-corticosteroid acute myopathy: Another piece to the puzzle
70. Critical illness' polyneuropathy: Clinical findings and outcomes of a frequent cause of neuromuscular weaning failure
71. Eye care for the mechanically ventilated patient receiving neuromuscular blockade or propofol
72. Atracurium resistance in a critically ill patient
73. Effect of prescribing guidelines on the use of neuromuscular blocking agents
74. A pharmacoeconomic analysis of neuromuscular blocking agents in the operating room
75. The impact of choice of muscle relaxant on postoperative recovery time: A retrospective study
76. Retro spective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients
77. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit
78. Do shorter-acting neuromuscular blocking drugs or opioids associate with reduced intensive care unit or hospital length of stay after coronary artery bypass grafting?